Payment overview · 2025
General Payments
$418.61
25 reported records · 7 companies
Healthcare provider profile · identity verified
John Raymond Durant, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DADEVILLE, AL · NPI 1790717858
Verified facts
What the public records show
CMS Open Payments records show John Raymond Durant, MD received $418.61 in general payments during 2025 across 25 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 45.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $191.16 | 45.7% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $74.57 | 17.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.18 | 13.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.64 | 8.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.57 | 5.4% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.42 | 5.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.07 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $418.61 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $191.16 | 13 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $74.57 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.18 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.64 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 87 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
87 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 469 | 158 |
| Losartan Potassium | Losartan Potassium | 419 | 135 |
| Pantoprazole Sodium | Pantoprazole Sodium | 414 | 157 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 386 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 295 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 74 |
| Trazodone Hcl | Trazodone Hcl | 271 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 260 | 94 |
| Gabapentin | Gabapentin | 245 | 64 |
| Azithromycin | Azithromycin | 211 | 162 |
| Metformin Hcl | Metformin Hcl | 202 | 67 |
| Meloxicam | Meloxicam | 194 | 71 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 180 | 60 |
| Fluconazole | Fluconazole | 172 | 97 |
| Pravastatin Sodium | Pravastatin Sodium | 168 | 59 |
| Omeprazole | Omeprazole | 158 | 55 |
| Tramadol Hcl | Tramadol Hcl | 154 | 34 |
| Clonazepam | Clonazepam | 150 | 25 |
| Potassium Chloride | Potassium Chloride | 147 | 54 |
| Carvedilol | Carvedilol | 143 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 44 |
| Lisinopril | Lisinopril | 112 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 103 | 46 |
| Colchicine | Colchicine | 96 | 33 |
| Eliquis | Apixaban | 94 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 28 |
| Montelukast Sodium | Montelukast Sodium | 90 | 39 |
| Ozempic | Semaglutide | 90 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 27 |
| Methocarbamol | Methocarbamol | 89 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 36 |
| Furosemide | Furosemide | 81 | 28 |
| Amoxicillin | Amoxicillin | 78 | 63 |
| Promethazine Hcl | Promethazine Hcl | 77 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 19 |
| Buspirone Hcl | Buspirone Hcl | 74 | 26 |
| Lorazepam | Lorazepam | 71 | 20 |
| Baclofen | Baclofen | 68 | 27 |
| Sertraline Hcl | Sertraline Hcl | 66 | 26 |
| Bupropion Xl | Bupropion Hcl | 63 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 47 |
| Sucralfate | Sucralfate | 62 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 23 |
| Simvastatin | Simvastatin | 59 | 20 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 58 | 24 |
| Clindamycin Hcl | Clindamycin Hcl | 56 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 16 |
| Clonidine Hcl | Clonidine Hcl | 55 | 18 |
| Allopurinol | Allopurinol | 53 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 37 |
| Meclizine Hcl | Meclizine Hcl | 52 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 16 |
| Farxiga | Dapagliflozin Propanediol | 49 | 18 |
| Ibuprofen | Ibuprofen | 48 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 21 |
| Mounjaro | Tirzepatide | 46 | 12 |
| Ondansetron Odt | Ondansetron | 46 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 11 |
| Famotidine | Famotidine | 44 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 26 |
| Penicillin V Potassium | Penicillin V Potassium | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | 14 |
| Spironolactone | Spironolactone | 41 | 14 |
| Ketoconazole | Ketoconazole | 40 | 23 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Glipizide Er | Glipizide | 39 | 13 |
| Mirtazapine | Mirtazapine | 38 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 31 |
| Alendronate Sodium | Alendronate Sodium | 37 | 11 |
| Jardiance | Empagliflozin | 37 | 15 |
| Naproxen | Naproxen | 37 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 36 | suppressed |
| Glipizide | Glipizide | 36 | 12 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Mupirocin | Mupirocin | 36 | 30 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Rexulti | Brexpiprazole | 35 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | 12 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Ezetimibe | Ezetimibe | 28 | 12 |
| Torsemide | Torsemide | 28 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Cimetidine | Cimetidine | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Nystatin | Nystatin | 21 | 17 |
| Risperidone | Risperidone | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | 14 |
| Rybelsus | Semaglutide | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 14 | 13 |
| Pentazocine-Naloxone Hcl | Pentazocine Hcl/Naloxone Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $418.61 · 25 records | Bayer Healthcare Pharmaceuticals Inc. | CAPLYTA, INGREZZA, Kerendia, OTEZLA, Ozempic, REPATHA, TRELEGY ELLIPTA, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error